Yahoo Finance

Estimated Discount To Fair Value: 45%

Deutsche Beteiligungs AG is trading significantly below its estimated fair value of €42.72, with a current price of €23.5, indicating potential undervaluation based on discounted cash flow analysis. Despite recent financial challenges, including a net loss of €35.23 million in Q4 2024 and negative revenue of €20.69 million, the company is expected to achieve profitability within three years and outpace the German market with forecasted annual revenue growth of 72.2%. However, its dividend yield remains unsustainable against earnings or free cash flows.

• The growth report we've compiled suggests that Deutsche Beteiligungs' future prospects could be on the up.

• Unlock comprehensive insights into our analysis of Deutsche Beteiligungs stock in this financial health report.

Formycon

Overview: Formycon AG is a biotechnology company that develops biosimilar drugs in Germany and Switzerland, with a market cap of €402.58 million.

Operations: The company's revenue primarily comes from its Drug Delivery Systems segment, which generated €69.67 million.

Estimated Discount To Fair Value: 45.9%

Formycon AG is trading at a significant discount to its estimated fair value of €42.13, with a current price of €22.8, suggesting undervaluation based on cash flow analysis. Despite reporting a net loss of €125.67 million for 2024, the company anticipates becoming profitable in three years and expects annual revenue growth of 18.4%, surpassing the German market's average growth rate. However, recent share price volatility could pose risks for investors focused on stability.

• Our expertly prepared growth report on Formycon implies its future financial outlook may be stronger than recent results.

• Click here to discover the nuances of Formycon with our detailed financial health report.

Summing It All Up

• Reveal the 192 hidden gems among our Undervalued European Stocks Based On Cash Flows screener with a single click here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HLSE:CAPMAN XTRA:DBAN and XTRA:FYB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com